Cover Image
Market Research Report

Global Nanopharmaceutical Drugs Market: Focus on Nanodrugs and its Application in Therapeutics, Competitive Landscape, and Country - Analysis and Forecast (2018-2026)

Published by BIS Research Inc. Product code 752401
Published Content info 267 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Nanopharmaceutical Drugs Market: Focus on Nanodrugs and its Application in Therapeutics, Competitive Landscape, and Country - Analysis and Forecast (2018-2026)
Published: November 30, 2018 Content info: 267 Pages
Description

Global Nanopharmaceutical Drugs Market is Expected to Reach $79.29 billion by 2026

The pharmaceutical industry is focused on the most emerging branch in pharmaceutical sciences known as" Pharmaceutical nanotechnology ". The increasing prevalence of chronic diseases/disorder and development of the healthcare infrastructure are promoting the adoption of the novel medicine known as nanomedicine for better efficacy and improved patient outcome.

Nanomedicine works on same principle of nanotechnology, as the materials at nanoscale level possess unique characteristics as compared to macroscopic level. Nanomedicine has a multidisciplinary nature involving notions and techniques from biology, chemistry, and physics. Nanotechnology provides exceptional benefits when applied to medical devices and pharmaceuticals. Furthermore, the patent cliff/expirations has the enabled the pharmaceutical companies to adopt new business strategies. Many blockbuster drugs are going off-patent but the introduction of nanotechnology in medicines has revolutionized the pharmaceutical industry. With the advancement in the Nano pharmaceutical industry, the number of patent filings has dramatically increased. Pharmaceutical companies have developed new strategies & techniques to re-patent drugs which are on the way to expiration by modifying them with the help of nanotechnology. Nanodrugs offers a promising potential in terms of revenue growth.

The purpose of this study is to gain a holistic view of the nanopharmaceutical drugs market in terms of various influencing factors such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the drugs associated with the global nanopharmaceutical drugs market across different regions. The market has been segmented into 'drug carrier type,' 'application,' 'distribution channel,' and 'regions.' The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering various aspects of the global nanopharmaceutical drugs market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter's Five Forces for a comprehensive understanding of the global nanopharmaceutical drugs market. Moreover, the study includes detailed product mapping with further sub-segmentation in various countries, and in each sub-segment, the key market trends, list of the key companies, and the key strategies and developments have also been discussed.

The answers to the following key questions can be derived from this report:

  • How did the Nanopharmaceutical Drugs market evolve, and what is its scope in the future?
  • What are the major market drivers, challenges, and opportunities in the global Nanopharmaceutical Drugs market?
  • What are the key developmental strategies that are implemented by the key players to sustain in this market?
  • How will the influencing factors affect the industry attractiveness?
  • How nanopharmaceutical Drugs is superior that conventional drugs?
  • How will the investments by public and private companies and government organizations affect the global nanopharmaceutical drugs market?
  • What was the market size of the leading segments and sub-segments of the global nanopharmaceutical drugs market in 2017?
  • How will the industry evolve during the forecast period 2018-2026?
  • What will be the growth rate of the nanopharmaceutical drugs during the forecast period?
  • How will each segment of the global nanopharmaceutical drugs market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2026?
  • Which drug carrier segment, application segment and distribution channel is expected to register the highest CAGR for the nanopharmaceutical drugs market?
  • What is the market size of nanopharmaceutical drugs in different countries of the world?
  • Which geographical region will contribute to the highest sales of nanopharmaceutical drugs?
  • Who are the key players in the nanopharmaceutical drugs market, and what are their contributions?

The key players who have been contributing significantly to the nanopharmaceutical drugs market include Pfizer, Inc, AstraZeneca, Gilead Sciences, and Astellas Pharma Inc., Abbvie Inc., Amgen, Merck & Co., Inc., Hoffmann-La Roche AG., Teva Pharmaceuticals Industries Limited, Novartis AG, CELGENE CORPORATION, Sanofi S.A., JOHNSON & JOHNSON, AMAG Pharmaceuticals and Shire plc., among others.

Executive Summary

Big pharma companies rely on blockbuster drugs for revenue generation. The patent protection allows the pharma company to sell the drugs at high profit margin, for example the Pfizer's drug known as Lipitor, accounts for about $13 bn of Pfizer's revenues. Many blockbuster drugs are going off patent, drug manufacturers are facing challenges to develop novel research and development strategies, involving miniaturization through various techniques including nanotechnology.

The introduction of nanotechnology in medicines has revolutionized the pharmaceutical industry. With the advancement in the Nano pharmaceutical industry, the number of patent filings has dramatically increased. Pharmaceutical companies have developed new strategies & techniques to re-patent drugs which are on the way to expiration by modifying them with the help of nanotechnology. Nanodrugs offers a promising potential in terms of revenue growth.

The nanopharmaceuticals have broach range of application and are used in imaging, diagnostics and therapeutics and possess full potential to dominate the pharmaceutical market. The introduction of nanomedicine will alter the landscape of medicine and will drastically improve a patient's quality of life and reduce healthcare costs.

The purpose of this study is to gain a holistic view of the nanopharmaceutical drugs market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the drugs associated with the global nanopharmaceutical drugs market across different regions. The market has been segmented into 'drug carrier type,' 'application,' 'distribution channel,' and 'regions.' The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market. The global nanopharmaceutical drug market is valued $40.37 billion in 2017 and is expected to reach $79.29 billion by 2026.

The major factor driving the growth of this market, are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in global healthcare expenditure, and rapid growth in the aging population. Further, the increasing insurance coverage and reimburesement policies in the developed markets such as the U.S., Japan, Germany, and the U.K. are the key drivers for the growth of the nanopharmaceutical drugs market.

Moreover, among different therapeutic areas, the oncology therapeutic area dominated the global nanopharmaceutical drugs market in 2017. Nanoparticles offer an opportunity to introduce overall shift in cancer research. Many drug candidates are under clinical investigation and have the potential to be introduced in the market. Ideal nanomedicines should follow the regulatory pathway of approval and should have a modular design that can be easily scaled up for cGMP manufacturing and stored for a long time prior to use in patients. The Nanotechnology Characterization Laboratory and FDA works in collaboration to advance and review nanomedicine platform.

On the basis of regions, the global nanopharmaceutical drugs market is segmented into North America, Europe, Asia-Pacific, and Rest-of-the-World (RoW). North America is the leading contributor to the global nanopharmaceutical drugs market and contributed 51.78% in terms of revenue respectively to the global market in 2017. However, Europe and Asia-Pacific is expected to grow at a significant CAGR between 5% to 7% in terms of revenue respectively, during the forecast period.

The key players who have been contributing significantly to the nanopharmaceutical drugs market include Pfizer, Inc, AstraZeneca, Gilead Sciences, and Astellas Pharma Inc., Abbvie Inc., Amgen, Merck & Co., Inc., Hoffmann-La Roche AG., Teva Pharmaceuticals Industries Limited, Novartis AG, CELGENE CORPORATION, Sanofi S.A., JOHNSON & JOHNSON, AMAG Pharmaceuticals and Shire plc., among others.

Table of Contents
Product Code: BH112A

Table of Contents

Executive Summary

1 Market Overview

  • 1.1 What are Nanopharmaceuticals?
  • 1.2 Historical Trends
  • 1.3 Comparative Analysis of Conventional Medicine and Nanomedicine
  • 1.4 Issues and Concerns in Nanotech Product Development and its Commercialization
  • 1.5 Impact of Market Drivers and Market Restraints
  • 1.6 Assumptions and Limitations for Market Size Calculations
  • 1.7 Global Nanopharmaceutical Drugs Market Scenario

2 Market Dynamics

  • 2.1 Impact Analysis
  • 2.2 Market Drivers
    • 2.2.1 Government Initiative
    • 2.2.2 Nanopharmaceuticals: A Hope for Patent Expired Formulations
    • 2.2.3 Increase in Number of Abbreviated New Drug Application (ANDA), Biologics License Application (BLA) Approvals: Closing the Gap for Generic Nanomedicines
    • 2.2.4 Nanomedicine - Innovative Ways of Treating Challenging Conditions
  • 2.3 Market Restraints
    • 2.3.1 Economic & Financial Barriers
    • 2.3.2 Undefined Regulatory Approvals
  • 2.4 Market Opportunities
    • 2.4.1 Pipeline Creating Market Opportunity
    • 2.4.2 The Nanomedicine Market: Small Particles - Big Business
  • 2.5 Market Trends
    • 2.5.1 Pfizer, Merck Focusing on Nanomedicine as Next Disruption in Pharma
    • 2.5.2 Trends in Approval and Development
    • 2.5.3 Publications Trend Scenario

3 Competitive Insights

  • 3.1 Pipeline Analysis and Market Opportunity
  • 3.2 Product Launches and Approvals

4 Industry Insights

  • 4.1 Introduction
  • 4.2 Patent Analysis
  • 4.3 Funding Scenario
  • 4.4 Regulatory Bodies

5 Global Nanopharmaceutical Drug Market (by Drug Carrier)

  • 5.1 Liposomes
  • 5.2 Polymer
  • 5.3 Nanocrystals
  • 5.4 Inorganic
  • 5.5 Protein
  • 5.6 Others

6 Global Nanopharmaceutical Drugs Market (by Application)

  • 6.1 Oncology
  • 6.2 Neurology
  • 6.3 Anti-inflammatory/Immunology
  • 6.4 Anti-infective
  • 6.5 Cardiovascular/Physiology
  • 6.6 Others

7 Global Nanopharmaceutical Drugs Market (by Distribution Channel)

  • 7.1 Hospital Pharmacies
  • 7.2 Retail Pharmacies
  • 7.3 Online Pharmacies

8 Global Nanopharmaceutical Drugs Market (by Region)

  • 8.1 North America
    • 8.1.1 The U.S.
    • 8.1.2 Canada
  • 8.2 Europe
    • 8.2.1 Germany
    • 8.2.2 France
    • 8.2.3 The U.K.
    • 8.2.4 Spain
    • 8.2.5 Italy
    • 8.2.6 Rest-of-Europe
  • 8.3 Asia-Pacific
    • 8.3.1 China
    • 8.3.2 Japan
    • 8.3.3 Rest-of-Asia-Pacific
  • 8.4 Rest-of-the-World

9 Company Profiles

Overview

  • 9.1 AbbVie Inc.
    • 9.1.1 Company Overview
    • 9.1.2 Role of Abbvie Inc. in Nanopharmaceuticals Drug Market
    • 9.1.3 Financials
    • 9.1.4 Key Insights about Financial Health of the Company
    • 9.1.5 Global Presence
    • 9.1.6 SWOT Analysis
  • 9.2 AMAG Pharmaceuticals
    • 9.2.1 Company Overview
    • 9.2.2 Role of AMAG Pharmaceutical in Global Nanopharmaceutical Drugs Market
    • 9.2.3 Financials
    • 9.2.4 Key Insights about Financial Health of the Company
    • 9.2.5 Global Presence
    • 9.2.6 SWOT Analysis
  • 9.3 Amgen Inc.
    • 9.3.1 Company Overview
    • 9.3.2 Role of Amgen Inc. in Nanopharmaceuticals Drug Market
    • 9.3.3 Financials
    • 9.3.4 Key Insights about Financial Health of the Company
    • 9.3.5 Global Presence
    • 9.3.6 SWOT Analysis
  • 9.4 Astellas Pharma Inc.
    • 9.4.1 Company Overview
    • 9.4.2 Role of Astellas Pharma Inc. in Global Nanopharmaceutical Drugs Market
    • 9.4.3 Financials
    • 9.4.4 Key Insights about Financial Health of the company
    • 9.4.5 SWOT Analysis
  • 9.5 AstraZeneca PLC
    • 9.5.1 Company Overview
    • 9.5.2 Role of AstraZeneca PLC in Global Nanopharmaceutical Drugs Market
    • 9.5.3 Financials
    • 9.5.4 Key Insights about Financial Health of the company
    • 9.5.5 Global Presence
    • 9.5.6 SWOT Analysis
  • 9.6 CELGENE CORPORATION
    • 9.6.1 Company Overview
    • 9.6.2 Role of CELGENE CORPORATION in Global Nanopharmaceutical Drugs Market
    • 9.6.3 Financials
    • 9.6.4 Key Insights about Financial Health of the company
    • 9.6.5 Global Presence
    • 9.6.6 SWOT Analysis
  • 9.7 Gilead Sciences, Inc.
    • 9.7.1 Company Overview
    • 9.7.2 Role of Gilead Sciences, Inc in Global Nanopharmaceutical Drugs Market
    • 9.7.3 Financials
    • 9.7.4 Key Insights about Financial Health of the company
    • 9.7.5 Global Presence
    • 9.7.6 SWOT Analysis
  • 9.8 JOHNSON & JOHNSON
    • 9.8.1 Company Overview
    • 9.8.2 Role of Johnson & Johnson in Global Nanopharmaceutical Drugs Market
    • 9.8.3 Financials
    • 9.8.4 Key Insights about Financial Health of the company
    • 9.8.5 Global Presence
    • 9.8.6 SWOT Analysis
  • 9.9 Merck & Co., Inc.
    • 9.9.1 Company Overview
    • 9.9.2 Role of Merck & Co., Inc. in Nanopharmaceutical Drugs Market
    • 9.9.3 Financials
    • 9.9.4 Key Insights about Financial Health of the company
    • 9.9.5 Global Presence
    • 9.9.6 SWOT Analysis
  • 9.10 Novartis AG
    • 9.10.1 Company Overview
    • 9.10.2 Role of Novartis AG in Nanopharmaceutical Drugs Market
    • 9.10.3 Financials
    • 9.10.4 Key Insights about Financial Health of the company
    • 9.10.5 Global Presence
    • 9.10.6 SWOT Analysis
  • 9.11 Pfizer, Inc.
    • 9.11.1 Company Overview
    • 9.11.2 Role of Pfizer, Inc. in the Pharmaceutical Drug Market
    • 9.11.3 Financials
    • 9.11.4 Key Insights on the Financial Health of the Company
    • 9.11.5 Global Presence
    • 9.11.6 SWOT Analysis
  • 9.12 Hoffmann-La Roche AG
    • 9.12.1 Company Overview
    • 9.12.2 Role of F. Hoffmann-La Roche AG in the Nanopharmaceutical Drugs Market
    • 9.12.3 Financials
    • 9.12.4 Key Insights about Financial Health of the company
    • 9.12.5 Global Presence
    • 9.12.6 SWOT Analysis
  • 9.13 Sanofi S.A
    • 9.13.1 Company Overview
    • 9.13.2 Role of Sanofi S.A in Global Nanopharmaceutical Drugs Market
    • 9.13.3 Financials
    • 9.13.4 Key Insights about Financial Health of the company
    • 9.13.5 Global Presence
    • 9.13.6 SWOT Analysis
  • 9.14 Shire Plc.
    • 9.14.1 Company Overview
    • 9.14.2 Role of Shire plc. In Global Nanopharmaceutical Drugs Market
    • 9.14.3 Financials
    • 9.14.4 Key Insights about Financial Health of the company
    • 9.14.5 Global Presence
    • 9.14.6 SWOT Analysis
  • 9.15 Teva Pharmaceuticals Industries Limited
    • 9.15.1 Company Overview
    • 9.15.2 Teva Pharmaceuticals Industries Limited in Nanopharmaceutical Drugs Market
    • 9.15.3 Financials
    • 9.15.4 Key Insights about Financial Health of the company
    • 9.15.5 Global Presence
    • 9.15.6 SWOT Analysis

10 Research Scope and Methodology

  • 10.1 Report Scope
  • 10.2 Global Nanopharmaceutical Drugs Market: Research Methodology

List of Tables

  • Table 1 Cancer Incidences (by Region), 2015
  • Table 2 Characterization Tools and Methods for Nanoparticles
  • Table 1.1 Various Characteristics and Brief Applications of Nanosystems
  • Table 1.2 Conventional Medicine vs. Nanomedicine
  • Table 2.1 Impact Analysis
  • Table 3.1 Drug Candidates in Different Phase of Development
  • Table 3.2 Nanopharmaceutical Drug Approvals
  • Table 4.1 Criterion for Patentability
  • Table 4.2 Selected Case Law Pertaining to Nanotechnology
  • Table 4.3 List of Regulatory Bodies across the World
  • Table 5.1 List of Liposome NPs
  • Table 5.2 List of Polymer NPs
  • Table 5.3 List of Nanocrystal NPs
  • Table 5.4 List of Inorganic NPs
  • Table 5.5 List of Protein NPs
  • Table 6.1 Currently Approved Nanomedicines in the Clinic (Cancer)
  • Table 8.1 North America Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017-2026, $B
  • Table 8.2 North America Nanopharmaceutical Drugs Market (by Application), 2017-2026, $Billion
  • Table 8.3 Europe Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017-2026
  • Table 8.4 Europe Nanopharmaceutical Drugs Market (by Application), 2017-2026
  • Table 8.5 Asia-Pacific Nanopharmaceutical Drugs Market(by Drug Carrier Type), 2017-2026
  • Table 8.6 Asia-Pacific Nanopharmaceutical Drugs Market, by Application, 2017-2026

List of Figures

  • Figure 1 Evolution of Nanomedicine
  • Figure 2 Global Nanopharmaceutical Drugs Market Share (by Drug Carrier Type), 2017
  • Figure 3 Global Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2018 - 2026
  • Figure 4 Global Nanopharmaceutical Drugs Market (by Application), 2018 - 2026
  • Figure 5 Global Nanopharmaceutical Drugs Market (by Distribution Channel), 2018 - 2026
  • Figure 6 Global Nanopharmaceutical Drug Market, (by Region), 2017, 2021, and 2026
  • Figure 7 Global Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 8 Global Nanopharmaceutical Drugs Market, 2017-2026, Y-o-Y
  • Figure 9 Nanomedicine Market: Impacting Factors
  • Figure 10 Global Nanopharmaceutical Drugs Market, Absolute Dollar Opportunity, Billion (by Region)
  • Figure 11 Global Nanopharmaceutical Drugs Market, Market Attractiveness (By Application)
  • Figure 1.1 Different Types of Biomarkers in Nanopharmaceutical Drug
  • Figure 1.2 Drug Particle Prepared in the Nanoscale Depends on Four Aspects of Nanopharmaceutical Lifestyle
  • Figure 1.3 Era of Nanodrug Delivery in Cancer
  • Figure 1.4 Introduction to Nanomedicine: Years of Commercialization
  • Figure 1.5 Concerns in Nanotech Product Development and its Commercialization
  • Figure 1.6 Impact of Market Drivers and Market Restraints
  • Figure 1.7 Global Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 2.1 Market Dynamics
  • Figure 2.2 NNI Budget (by Agency), 2017-2019 (Proposed)
  • Figure 2.3 Number of ANDA Approvals, 2017
  • Figure 2.4 Nanotechnology Business
  • Figure 2.5 Pipeline Drugs: Clinical Opportunity
  • Figure 2.6 Pipeline Drugs: On Map
  • Figure 2.7 Nano based Drug Delivery Patent Filing, (By Region), 2015
  • Figure 2.8 Nanoparticles in Approved and Investigational Drugs, 2017
  • Figure 3.1 Market Potential, Drug Peak Sale ($Billion)
  • Figure 4.1 Industry Insights
  • Figure 4.2 Patent Expiration (By Drug Carrier Type), 2016
  • Figure 5.1 Types of Nanocarriers
  • Figure 5.2 Global Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017 and 2026
  • Figure 5.3 Global Nanopharmaceutical Drugs Market (by Liposome Drug Carrier), 2017-2026
  • Figure 5.4 Global Nanopharmaceutical Drugs Market (by Polymer NP), 2017-2026
  • Figure 5.5 Global Nanopharmaceutical Drugs Market (by Nanocrystal Drug Carrier), 2017-2026
  • Figure 5.6 Global Nanopharmaceutical Drugs Market (by Inorganic), 2017-2026
  • Figure 5.7 Global Nanopharmaceutical Drugs Market (by Protein Drug Carrier), 2017-2026
  • Figure 5.8 Global Nanopharmaceutical Drugs Market (by Other Drug Carrier), 2017-2026
  • Figure 6.1 Global Nanopharmaceutical Drugs Market (by Application)
  • Figure 6.2 Global Nanopharmaceutical Drugs Market (by Products), 2017-2026
  • Figure 6.3 Global Nanopharmaceutical Drugs Market (by Oncology), 2017-2026
  • Figure 6.4 Nanomedicine in Neurology
  • Figure 6.5 Global Nanopharmaceutical Drugs Market (by Neurology), 2017-2026
  • Figure 6.6 Global Nanopharmaceutical Drugs Market (by Anti-inflammatory/Immunology), 2017-2026
  • Figure 6.7 Global Nanopharmaceutical Drugs Market (by Anti-infectives), 2017-2026
  • Figure 6.8 Global Nanopharmaceutical Drugs Market (by Cardiovascular and Physiology), 2017-2026
  • Figure 6.9 Global Nanopharmaceutical Drugs Market (by Other Application Areas), 2017-2026
  • Figure 7.1 Global Nanopharmaceutical Drugs Market (by Distribution Channel), 2017-2026
  • Figure 7.2 Global Nanopharmaceutical Drugs Market (by Hospital Pharmacy), 2017-2026
  • Figure 7.3 Global Nanopharmaceutical Drugs Market (by Retail and Drug Store), 2017-2026
  • Figure 7.4 Global Nanopharmaceutical Drugs Market (by Online Pharmacy), 2017-2026
  • Figure 8.1 Global Nanopharmaceutical Drugs Market Scenario, (CAGR), 2018-2026, (Market Value), (2017)
  • Figure 8.2 Global Nanopharmaceutical Drugs Market (by Region), 2017-2026
  • Figure 8.3 Global Nanopharmaceutical Drugs Market Share (by Region), 2017 and 2026
  • Figure 8.4 North America Nanopharmaceutical Drugs Market, (2017-2026)
  • Figure 8.5 North America Market Dynamics
  • Figure 8.6 North America Nanopharmaceutical Drugs Market (by Country), 2017-2026
  • Figure 8.7 The U.S Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 8.8 Canada Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 8.9 Europe Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 8.10 Europe Market Dynamics
  • Figure 8.11 Europe Nanopharmaceutical Drugs Market (by Country), 2017-2026
  • Figure 8.12 Germany Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 8.13 France Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 8.14 The U.K. Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 8.15 Spain Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 8.16 Italy Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 8.17 Rest-of-Europe Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 8.18 Asia-Pacific Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 8.19 Asia-Pacific Market Dynamics
  • Figure 8.20 Asia Pacific Nanopharmaceutical Drugs Market (by Country), 2017-2026
  • Figure 8.21 China Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 8.22 Japan Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 8.23 Rest-of-Asia Pacific Nanopharmaceutical Drugs Market, 2017-2026
  • Figure 8.24 Rest-of-the-World Nanopharmaceutical Drugs Market, (by Drug Carrier), 2017-2026
  • Figure 8.25 Rest-of-the-World Nanopharmaceutical Drugs Market, (by Application), 2017-2026
  • Figure 9.1 Abbvie Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
  • Figure 9.2 Abbvie Inc.: Overall Financials, 2015-2017
  • Figure 9.3 Abbvie Inc.: Revenue (by Region), 2015, 2016 and 2017
  • Figure 9.4 Abbvie Inc.: R&D Expense, 2015-2017
  • Figure 9.5 Abbvie Inc.: Revenue Forecast, 2015-2020
  • Figure 9.6 Abbvie Inc.: Global Presence
  • Figure 9.7 Abbvie Inc.: SWOT Analysis
  • Figure 9.8 AMAG Pharmaceuticals: Product Offerings for Global Nanopharmaceutical Drugs Market
  • Figure 9.9 AMAG Pharmaceuticals: Overall Financials, 2015-2017
  • Figure 9.10 AMAG Pharmaceuticals: Revenue (by Business Segment), 2015-2017
  • Figure 9.11 AMAG Pharmaceuticals: R&D Expense, 2015-2017
  • Figure 9.12 AMAG Pharmaceuticals: Revenue Forecast, 2015-2020
  • Figure 9.13 AMAG Pharmaceuticals: Global Presence
  • Figure 9.14 AMAG Pharmaceuticals: SWOT Analysis
  • Figure 9.15 Amgen, Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
  • Figure 9.16 Abbvie Inc.: Overall Financials, 2015-2017
  • Figure 9.17 Amgen Inc.: Revenue (by Region), 2015, 2016 and 2017
  • Figure 9.18 Amgen, Inc.: R&D Expense, 2015-2017
  • Figure 9.19 Amgen, Inc.: Revenue Forecast, 2015-2020
  • Figure 9.20 Amgen Inc.: Global Presence
  • Figure 9.21 Amgen, Inc.: SWOT Analysis
  • Figure 9.22 Astellas Pharma Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
  • Figure 9.23 Astellas Pharma Inc: Overall Financials, 2015-2017
  • Figure 9.24 Astellas Pharma Inc: Revenue (by Business Segment), 2016-2017
  • Figure 9.25 Astellas Pharma Inc.: Revenue (by Region), 2016-2017
  • Figure 9.26 Astellas Pharma Inc: R&D Expense, 2015-2017
  • Figure 9.27 AstraZeneca PLC: Revenue Forecast, 2015-2020
  • Figure 9.28 Astella Pharma Inc, SWOT Analysis
  • Figure 9.29 AstraZeneca PLC: Overall Financials, 2015-2017
  • Figure 9.30 AstraZeneca PLC: Revenue (by Region), 2015-2017
  • Figure 9.31 AstraZeneca PLC: R&D Expense, 2015-2017
  • Figure 9.32 AstraZeneca PLC: Global Presence
  • Figure 9.33 AstraZeneca PLC: SWOT Analysis
  • Figure 9.34 CELGENE CORPORATION: Product Offerings for Global Nanopharmaceutical Drugs Market
  • Figure 9.35 CELGENE CORPORATION: Overall Financials, 2015-2017
  • Figure 9.36 CELGENE CORPORATION: Revenue (by Region), 2015-2017
  • Figure 9.37 CELGENE CORPORATION: R&D Expense, 2015-2017
  • Figure 9.38 CELGENE CORPORATION: Revenue Forecast, 2015-2020
  • Figure 9.39 CELGENE CORPORATION: Global Presence
  • Figure 9.40 CELGENE CORPORATION: SWOT Analysis
  • Figure 9.41 Gilead Sciences, Inc: Product Offerings for Global Nanopharmaceutical Drugs Market
  • Figure 9.42 Gilead Sciences, Inc: Overall Financials, 2015-2017
  • Figure 9.43 Gilead Sciences, Inc: Revenue (by Region), 2015-2017
  • Figure 9.44 Gilead Sciences, Inc: R&D Expense, 2015-2017
  • Figure 9.45 Gilead Sciences, Inc: Revenue Forecast, 2015-2020
  • Figure 9.46 Gilead Sciences, Inc: Global Presence
  • Figure 9.47 Gilead Sciences, Inc: SWOT Analysis
  • Figure 9.48 Johnson & Johnson: Product Offerings for Global Nanopharmaceutical Drugs Market
  • Figure 9.49 Johnson & Johnson: Overall Financials, 2015-2017
  • Figure 9.50 Johnson & Johnson: Revenue (by Business Segment), 2015-2017
  • Figure 9.51 Johnson & Johnson: Revenue (by Region), 2015-2017
  • Figure 9.52 Johnson & Johnson: R&D Expense, 2015-2017
  • Figure 9.53 Johnson & Johnson: Revenue Forecast, 2015-2020
  • Figure 9.54 Johnson & Johnson: Global Presence
  • Figure 9.55 Johnson & Johnson: SWOT Analysis
  • Figure 9.56 Merck & Co., Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
  • Figure 9.57 Merck & Co., Inc.: Overall Financials, 2015-2017
  • Figure 9.58 Merck & Co., Inc.: Revenue (by Business Segment), 2015-2017
  • Figure 9.59 Merck & Co., Inc.: Revenue (by Region), 2015-2017
  • Figure 9.60 Merck & Co., Inc.: R&D Expense, 2015-2017
  • Figure 9.61 Merck & Co., Inc.: Revenue Forecast, 2015-2020
  • Figure 9.62 Merck & Co., Inc.: Global Presence
  • Figure 9.63 Merck & Co., Inc.: SWOT Analysis
  • Figure 9.64 Novartis AG: Product Offerings for Global Nanopharmaceutical Drugs Market
  • Figure 9.65 Novartis AG: Overall Financials, 2015-2017
  • Figure 9.66 Novartis AG: Revenue (by Business Segment), 2015-2017
  • Figure 9.67 Novartis AG: Revenue (by Region), 2015-2017
  • Figure 9.68 Novartis AG: R&D Expense, 2015-2017
  • Figure 9.69 Novartis AG: Revenue Forecast, 2015-2020
  • Figure 9.70 Novartis AG: Global Presence
  • Figure 9.71 Novartis AG: SWOT Analysis
  • Figure 9.72 Pfizer, Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
  • Figure 9.73 Pfizer, Inc.: Overall Financials, 2015-2017
  • Figure 9.74 Pfizer, Inc.: Revenue (by Business Segment), 2015, 2016 and 2017
  • Figure 9.75 Pfizer, Inc.: Revenue (by Region), 2015, 2016 and 2017
  • Figure 9.76 Pfizer, Inc.: R&D Expense, 2015-2017
  • Figure 9.77 Pfizer, Inc.: Revenue Forecast, 2015-2020
  • Figure 9.78 Pfizer, Inc.: Global Presence
  • Figure 9.79 Pfizer, Inc.: SWOT Analysis
  • Figure 9.80 F. Hoffmann-La Roche AG: Product Offerings for Global Nanopharmaceutical Drugs Market
  • Figure 9.81 F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
  • Figure 9.82 F. Hoffmann-La Roche AG: Revenue (by Business Segment), 2015-2017
  • Figure 9.83 F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017
  • Figure 9.84 F. Hoffmann-La Roche AG: R&D Expense, 2015-2017
  • Figure 9.85 F. Hoffmann-La Roche AG: Revenue Forecast, 2015-2020
  • Figure 9.86 F. Hoffmann-La Roche AG: Global Presence
  • Figure 9.87 F. Hoffmann-La Roche AG: SWOT Analysis
  • Figure 9.88 Sanofi S.A.: Product Offerings for Global Nanopharmaceutical Drugs Market
  • Figure 9.89 Sanofi S.A: Overall Financials, 2015-2017
  • Figure 9.90 Sanofi S.A: Revenue (by Business Segment), 2015-2017
  • Figure 9.91 Sanofi S.A: Revenue (by Region), 2015-2017
  • Figure 9.92 Sanofi S.A: R&D Expense, 2015-2017
  • Figure 9.93 Sanofi S.A: Revenue Forecast, 2015-2020
  • Figure 9.94 Sanofi S.A: Global Presence
  • Figure 9.95 Sanofi S.A: SWOT Analysis
  • Figure 9.96 Shire plc.: Product Offerings for Global Nanopharmaceutical Drugs Market
  • Figure 9.97 Shire plc.: Overall Financials, 2015-2017
  • Figure 9.98 Shire PLC: Revenue (by Business Segment), 2015-2017
  • Figure 9.99 Shire PLC: R&D Expense, 2015-2017
  • Figure 9.100 Shire PLC: Revenue Forecast, 2015-2020
  • Figure 9.101 Shire PLC: Global Presence
  • Figure 9.102 Shire PLC: SWOT Analysis
  • Figure 9.103 Teva Pharmaceuticals Industries Limited: Product Offerings for Global Nanopharmaceutical Drugs Market
  • Figure 9.104 Teva Pharmaceuticals Industries Limited: Overall Financials, 2015-2017
  • Figure 9.105 Teva Pharmaceuticals Industries Limited: Revenue (by Business Segment), 2015-2017
  • Figure 9.106 Teva Pharmaceuticals Industries Limited: Revenue (by Region), 2015-2017
  • Figure 9.107 Teva Pharmaceuticals Industries Limited: R&D Expense, 2015-2017
  • Figure 9.108 Teva Pharmaceuticals Industries Limited: Revenue Forecast, 2015-2020
  • Figure 9.109 Teva Pharmaceuticals Industries Limited: Global Presence
  • Figure 9.110 Teva Pharmaceuticals Industries Limited: SWOT Analysis
  • Figure 10.1 Global Nanopharmaceutical Drugs Market Scope
  • Figure 10.2 Global Nanopharmaceutical Drugs Market: Research Methodology
  • Figure 10.3 Primary Research
  • Figure 10.4 Secondary Research
  • Figure 10.5 Data Triangulation
  • Figure 10.6 Top-down Approach (Segment-wise Analysis)
  • Figure 10.7 Bottom-up Approach (Segment-wise Analysis)
  • Figure 10.8 Assumptions and Limitations
  • Figure 10.9 Considered Factors for Data Prediction and Modelling
Back to Top